The main clinical interest of IDO1 inhibitors has been in combination with anti-PD-1 agents [233], especially that preclinical in vivo studies demonstrated significant synergy and increased tumor shrinkage with this combination as compared to anti-PD-1 monotherapy. Here, IDO1 is linked to neoplasm.